


PRODUCT INFORMATION



Limaprost

Item No. 13810

CAS Registry No.: 74397-12-9
Formal Name: 11 α ,15S-dihydroxy-17S,20-dimethyl-9-oxo-prosta-2E,13E-dien-1-oic acid
Synonyms: 17 α ,20-dimethyl- Δ^2 -PGE₁, 17 α ,20-dimethyl- Δ^2 -Prostaglandin E₁
MF: C₂₂H₃₆O₅
FW: 380.5
Purity: \geq 98%
Supplied as: A crystalline solid
Storage: -20°C
Stability: \geq 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Limaprost is supplied as a crystalline solid. A stock solution may be made by dissolving the limaprost in the solvent of choice, which should be purged with an inert gas. Limaprost is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of limaprost in these solvents is approximately 50, 130, and 30 mg/ml, respectively.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of limaprost can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of limaprost in PBS (pH 7.2) is approximately 2 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Limaprost is an analog of PGE₁ with structural modifications intended to give it a prolonged half-life and greater potency. Limaprost is orally active in both rats and guinea pigs at doses of 100 μ g/kg as an inhibitor of ADP and collagen induced platelet aggregation. Limaprost is 10-1,000 times more potent than PGE₁ as an inhibitor of platelet adhesiveness measured *in vitro*. Intra-coronary injection (100 ng/kg) or intravenous injection (3 μ g/kg) in anesthetized dogs causes vasodilation and increased coronary blood flow by 60-80%. Significant hypotensive effects were seen at 100 and 300 μ g/kg orally in rats.{6808}

Reference

1. Tsuboi, T., Hatano, N., Nakatsuji, K., *et al.* Pharmacological evaluation of OP 1206, a prostaglandin E₁ derivative, as an antianginal agent. *Arch. Int. Pharmacodyn. Ther.* **247(1)**, 89-102 (1980).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/13/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM